

IN THE SPECIFICATION

AMENDMENTS TO THE SPECIFICATION

(added text shown with underlining; deleted text shown ~~by strikethrough~~)

1. On page 1, after the title, "PEPTIDE YY ANALOGS," please insert the following **new** paragraph:

--This application is a United States national stage filing under 35 U.S.C. §371 of international (PCT) application no. PCT/US2004/000892, filed January 13, 2004, and designating the US, which claims priority to US provisional application 60/440,812 filed January 17, 2003.--

2. On page 6, please amend paragraph 24 as follows:

--A⁵ is ~~Inc~~, or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Inc and Oic, or the N-methylated variant of Inc or of said D- or L- amino acid, or is deleted;--

3. On page 6, please amend paragraph 27 as follows:

--A⁸ is ~~Inc~~, or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Inc and Oic, or the N-methylated variant of Inc or of said D- or L- amino acid, or is deleted;--

4. On page 7, please amend paragraph 33 as follows:

--A¹⁴ is ~~Inc~~, or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Inc and Oic, or the N-methylated variant of Inc or of said D- or L- amino acid, or is deleted;--

5. On page 7, please amend paragraph 41 as follows:

--A²² is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Aib, Abu, Val, and Nva, or the N-methylated variant of Ala, Acc, Act, Aib, Apc, or Gly, or of said D- or L- amino acid, or is deleted;--

6. On page 8, please amend paragraph 42 as follows:

--A²³ is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Trp, Ser, Thr, Ala, Abu, and Val, or the N-methylated variant of Acc, Act, or Aib, or of said D- or L- amino acid, or is deleted;--

7. On page 8, please amend paragraph 44 as follows:

--A²⁵ is Acc, Aib, or ~~Aib~~Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, Aib, and HN-CH((CH₂)_n-N(R⁴R⁵))-C(O), or the N-methylated variant of Acc, Aib, or ~~Aib~~Apc, or of said D- or L- amino acid, or is deleted;--

8. On page 10, please amend paragraph 66 as follows:

--(iii) Apc at A⁴, A⁷, A¹², A¹⁹, A²², A²⁵, A²⁶, A³³, A³⁴, A³⁵, or A³⁶;--

9. On page 23, please amend paragraph 393 as follows:

-- Ac-[A6C³¹]hPYY(24-36)NH₂; (SEQ ID NO. 30)
Ac-(A6c²⁴)hPYY(24-36)NH₂; (SEQ ID NO. 64)--

10. On page 25, please amend paragraph 426 as follows:

--Ac-[4Pal²⁶]hPYY(22-36)NH₂; (SEQ ID NO. 13)
Ac-(A6c²⁴)hPYY(24-36)NH₂; (SEQ ID NO. 64)--

11. On page 34, please amend paragraph 463 as follows:

--The compounds of the invention are also useful for inhibiting small intestinal fluid and electrolyte secretion, and augmenting nutrient transport, as well as increasing cell proliferation in the gastrointestinal tract, regulating lipolysis in, e.g., ~~adipase~~ adipose tissue and regulating blood flow in a mammal.--

12. On page 37, please amend paragraph 474 as follows:

--- Examples 3 - 28 can be and were prepared substantially according to the procedures disclosed in Examples 1 and 2, above.

Ex.	Compound	SEQ ID NO.	Purity (HPLC)	Mol. Wt. (ESI-MS)	Mol. Wt. (Calculated)
3.	[3Pal ²⁶]hPYY(3-36)NH ₂	5	99.9	4060.0	4060.5
4.	[Taz ²⁶]hPYY(3-36)NH ₂	6	95.6	4066.2	4066.6
5.	[Apc ³⁵]hPYY(3-36)NH ₂	7	94.1	4019.0	4019.5
6.	[A6C ²⁸]hPYY(3-36)NH ₂	8	96.8	4062.0	4061.5
7.	[A6C ³⁰]hPYY(3-36)NH ₂	9	99.9	4062.0	4061.5
8.	[A6C ²⁴]hPYY(3-36)NH ₂	10	96.5	4062.0	4061.5
9.	[Aib ²²]hPYY(3-36)NH ₂	11	97.7	4064.0	4063.5
10.	[(3,4,5-F)Phe ²⁷]hPYY(3-36)NH ₂	12	99.9	4087.2	4087.5
11.	Ac-[4Pal ²⁶]hPYY(22-36)NH ₂	13	99.9	1942.0	1942.3
12.	Ac-[3Pal ²⁶]hPYY(22-36)NH ₂	14	99.0	1941.7	1942.3
13.	Ac-[(3,4,5-F)Phe ²⁷]hPYY(22-36)NH ₂	15	100	1969.2	1969.2
14.	Ac-(3Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂	16	97.2	1797.7	1798.1
15.	Ac-(4Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂	17	97.0	1797.7	1798.1
16.	Ac-(2Pal ²⁶ , Leu ³¹)hPPY(24-36)NH ₂	18	94.8	1797.9	1798.1
17.	Ac-(Taz ²⁶ , Leu ³¹)hPPY(24-36)NH ₂	19	97.9	1803.4	1804.2
18.	Ac-[Taz ²⁶]hPYY(22-36)NH ₂	20	97.9	1948.3	1948.3
19.	Ac-[A6c ³¹]hPYY(22-36)NH ₂	21	99.9	1957.2	1957.3
20.	Ac-[A6c ³⁰]hPYY(22-36)NH ₂	22	99.0	1942.9	1943.2
21.	Ac-[A6c ²⁸]hPYY(22-36)NH ₂	23	99.9	1942.8	1943.2
22.	Ac-[A5c ³¹]hPYY(22-36)NH ₂	24	99.9	1942.6	1943.2
23.	Ac-[A6C ²⁴]hPYY(22-36)NH ₂	25	99.9	1943.2	1943.2
24.	Ac-[D2Pal ²⁶]hPYY(22-36)NH ₂	26	96.0	1941.9	1942.3
25.	Ac-[2Pal ²⁶]hPYY(22-36)NH ₂	27	99.6	1941.8	1942.3
26.	Ac-[A6C ²⁴ , Leu ³¹]hPYY(24-36)NH ₂	28	97.5 <u>98.8</u>	1798.9	1799.1
27.	Ac-[A6C ²⁸ , Leu ³¹]hPYY(24-36)NH ₂	29	96.3 <u>97.5</u>	1798.9	1799.1
28.	AC-[A6C ³¹]HPYY(24-36)NH ₂	30	98.8 <u>96.3</u>	1798.9	1799.1--